Business
Licenses Vaccitech technology to advance Modi-2
Licenses Vaccitech technology to advance Modi-2.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \n \n 7 November 2022\n \n \n \n \n \n \n Scancell Holdings plc\n \n \n \n (\"Scancell\" or the \"Company\")\n \n \n \n \n \n \n Scancell in-licenses Vaccitech technology to advance Modi-2 towards the clinic\n \n \n \n \n \n \n \n \n \n SNAPvax™ technology to provide optimal method of formulation for Modi-2\n \n \n \n \n \n \n \n \n \n Company expects to initiate a Phase 1 clinical study with Modi-2 in 2024\n \n \n \n \n \n \n \n \n Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies, today announces it has in-licensed the SNAPvax™ technology from Vaccitech plc, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapies and vaccines. This agreement will allow Scancell to formulate and manufacture Modi-2, with the aim of initiating a Phase 1 clinical study in cancer patients in 2024.\n \n \n \n \n \n Modi-2 is the second product from the Company's Moditope® platform, which leverages the immune system to target a unique class of post-translational modifications (PTMs) upregulated by many cancers.\n The SNAPvax™ technology enables peptides to self-assemble with TLR-7/8a, a powerful adjuvant, to promote strong T cell responses and is proven to successfully\n overcome formulation issues associated with immunogenic peptide antigens, which are often highly hydrophobic and prone to manufacturing challenges with conventional formulations1.\n Modi-2 will use SNAPvax™ to codeliver homocitrullinated peptide antigens and TLR-7/8a adjuvants in self-assembling nanoparticles designed to prime tumour killing T cells.\n The Company expects that the combination of Scancell's\n Modi-2 with a highly effective platform for inducing T cells (Vaccitech's SNAPvax™ technology) will lead to a potentially superior therapeutic vaccine candidate.\n \n \n \n \n \n Scancell's Moditope® platform also consists of Modi-1, which is currently in a Phase 1 clinical study. Modi-1 targets\n citrullinated proteins,\n in contrast to Modi-2 which targets\n homocitrullinated proteins.\n Homocitrullination is a process that occurs by a different mechanism compared to citrullination and is therefore applicable to a distinct set of highly immune suppressed tumours. Scancell will leverage its deep understanding of T cell immunology and cancer immunotherapy toge...